Contribution: Industrial Research Assistance Program – Contributions to Firms
Sussex Research Laboratories Inc.
$899,670.00
UK BioM- 10138929 - EXHEPA_TARG_HAGL_GBP - Extrahepatic Targeting of Therapeutic Payloads Via High Affinity Glycan Ligands and Glycan Binding Proteins
FY 2025-26 · 2025-04-01
Summary
This project will develop an innovative platform for delivering mRNA therapies with enhanced precision to specific cells. It moves beyond traditional delivery methods by incorporating glycan-based targeting ligands, which offer a new active targeting approach. This strategy has broad therapeutic applications, with the potential to greatly improve treatment outcomes.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Ottawa|Ottawa, Ontario, Canada
Recipient Type
For-profit organization
Business Number
897184792
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2027-03-30
Agreement Number
1029473
Agreement Start Date
2025-04-01
Agreement Title
UK BioM- 10138929 - EXHEPA_TARG_HAGL_GBP - Extrahepatic Targeting of Therapeutic Payloads Via High Affinity Glycan Ligands and Glycan Binding Proteins
Agreement Title (French)
UK BioM- 10138929 - EXHEPA_TARG_HAGL_GBP — Ciblage extrahépatique de charges thérapeutiques via des ligands glycanes à haute affinité et des protéines de liaison glycanes
Agreement Type
Contribution
Agreement Value
$899,670.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project will develop an innovative platform for delivering mRNA therapies with enhanced precision to specific cells. It moves beyond traditional delivery methods by incorporating glycan-based targeting ligands, which offer a new active targeting approach. This strategy has broad therapeutic applications, with the potential to greatly improve treatment outcomes.
Description (French)
Ce projet permettra de développer une plateforme innovante pour administrer des thérapies à base d’ARNm avec une précision accrue à des cellules spécifiques. Il va au-delà des méthodes d’administration traditionnelles en incorporant des ligands de ciblage à base de glycanes, qui offrent une nouvelle approche de ciblage actif. Cette stratégie a de larges applications thérapeutiques et pourrait améliorer considérablement les résultats des traitements.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Ottawa--Vanier
Federal Riding (French)
Ottawa--Vanier
Federal Riding Number
35078
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
897184792
Recipient City
Ottawa|Ottawa
Recipient Country
CA
Recipient Legal Name
Sussex Research Laboratories Inc.
Recipient Postal Code
K1A 0R6
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2025-2026-Q1-1029473
